Skip to main content
. 2017 Apr 10;13(6):4002–4012. doi: 10.3892/ol.2017.6016

Figure 2.

Figure 2.

Effect of the combined treatment of irinotecan and OOS® in the viability of C26 cells. The viability of C26 cells was tested in the presence of OOS® (1:100), irinotecan (50 µM) or the combination of OOS® and irinotecan (1:100 and 50 µM) for 48 h. Then, the viability was quantified in untreated (black) and treated (grey) cells. Data are mean values ± SD from three different experiments. Differences in the viability of treated cells vs. untreated cells (**) and vs. initially cultured cells (*) were considered to be statistically significant at P<0.05.